Date:3/4/2013

, Spain, Revenue Forecast ($m), 2011-2019 30
Figure 23: Idiopathic Thrombocytopenic Purpura, Japan, Revenue Forecast ($m), 2011-2019 31
Figure 24: Idiopathic Thrombocytopenic Purpura, Total Market, Average Annual Cost of Therapy (%), 2011-2019 32
Figure 25: Idiopathic Thrombocytopenic Purpura, Treatment Usage Pattern ('000), 2011-2019 33
Figure 26: Idiopathic Thrombocytopenic Purpura, Pipeline Overview 35
Figure 27: Idiopathic Thrombocytopenic Purpura, Pipeline, Phase I by Therapeutic Class 36
Figure 28: Idiopathic Thrombocytopenic Purpura, Pipeline, Phase II Molecule Comparison 37
Figure 29: Idiopathic Thrombocytopenic Purpura, Pipeline, Phase III Molecule Comparison 39
Figure 30: Idiopathic Thrombocytopenic Purpura, Pipeline by Therapeutic Class 40
Figure 31: Idiopathic Thrombocytopenic Purpura, Pipeline by Molecule Type 40
Figure 32: Idiopathic Thrombocytopenic Purpura, Pipeline by Mechanism of Action 41
Figure 33: Myelodysplastic Syndrome, Total Market, Revenue Forecast ($m), 2011-2019 45
Figure 34: Myelodysplastic Syndrome, US, Revenue Forecast ($m), 2011-2019 46
Figure 35: Myelodysplastic Syndrome, UK, Revenue Forecast ($m), 2011-2019 46
Figure 36: Myelodysplastic Syndrome, France, Revenue Forecast ($m), 2011-2019 47
Figure 37: Myelodysplastic Syndrome, Germany, Revenue Forecast ($m), 2011-2019 47
Figure 38: Myelodysplastic Syndrome, Italy, Revenue Forecast ($m), 2011-2019 48
Figure 39: Myelodysplastic Syndrome, Spain, Revenue Forecast ($m), 2011-2019 48
Figure 40: Myelodysplastic Syndrome, Japan, Revenue Forecast ($m), 2011-2019 49
Figure 41: Myelodysplastic Syndrome, Total Market, Average Annual Cost of Therapy (%), 2011-2019 50
Figure 42: Myelodysplastic Syndrome, Treatment Usage Pattern ('000), 2011
'/>"/>

SOURCE Reportlinker Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related medicine technology :

1. Founder of Nestle-Acquired Company Joins Prismic Pharmaceuticals
2. Young Innovations Announces Definitive Agreement to be Acquired by Linden Capital Partners
3. Bandages Plus, Inc. Doral, Florida has been acquired by The Morrissey Group, LLC
4. Pathogenica and Life Technologies EMEA Partner to Control Hospital Acquired Infections
5. Medisafe 1 Technologies Corp has of Today Acquired 3,100,000 Shares and Continues to Acquire Shares Under its $1MM Stock Repurchase Program of 10MM Shares up to 10 Cents a Share to Facilitate its On-going Acquisitions Activity Plan
6. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
7. Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash
8. FDA Grants Orphan Drug Status To Eisais Lenvatinib
9. Lentigen Receives U.S. Orphan Drug Designation for Novel Gene Therapy for glioblastoma multiforme
10. BHR Pharma Investigational Traumatic Brain Injury Treatment Receives European Medicines Agency Orphan Medicinal Product Designation
11. Inherited Orphan Blood Disorders Therapeutics Market to 2019 - Breakthrough Drugs Remain Elusive Against Backdrop of High Unmet Need